ANDA 90794, held by Xiromed. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 90794 (Estarylla), held by Xiromed, was first approved by FDA on Jan 30, 2013, with 4 approved supplements and 0 published complete response letters.
Estarylla (norgestimate and ethinyl estradiol tablets, USP),are an estrogen/progestin COCs, indicated for use by women to prevent pregnancy. 1.1 Oral Contraceptive Estarylla (norgestimate and ethinyl estradiol tablets) are indicated for use by females of reproductive potential to prevent pregnancy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 30, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Estarylla0.035MG;0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Apr 29, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Feb 3, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 31, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 31, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 30, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters